Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 microg administered either in a once-daily in the morning regimen (160 microg qd AM) for 16 weeks or in a 160 microg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 microg bid) for 4 weeks, or in an 80 microg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids.

Next Previous
X
Search
Trial Profile

A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 microg administered either in a once-daily in the morning regimen (160 microg qd AM) for 16 weeks or in a 160 microg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 microg bid) for 4 weeks, or in an 80 microg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 20 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
    • 22 Dec 2008 Actual patient number (708) added as reported by ClinicalTrials.gov.
    • 20 Apr 2007 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top